checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


OTEZLA significantly improves palmoplantar psoriasis1

OTEZLA cleared or almost cleared psoriasis on the palms and soles of feet1

 

SIGNIFICANTLY MORE PATIENTS CLEAR OR ALMOST CLEAR
VS PLACEBO1,a,b

palmoplantar psoriasis treatment
a

Post-hoc analysis of pooled patient data from the phase IIb PSOR-005 and phase III ESTEEM® 1 and ESTEEM 2 studies. Among patients moderate to severe palmoplantar psoriasis (PPPGA score ≥3); was present in 144 patients (10.1%).

b

P = 0.021.

ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PPPGA, Palmoplantar Psoriasis Physician’s Global Assessment.

Reference: 1. Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016;75(1):99-105.


Select an e-mail client to share

close x